Forte Biosciences (NASDAQ:FBRX – Get Free Report) and Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Forte Biosciences and Pasithea Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Forte Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Pasithea Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Forte Biosciences presently has a consensus target price of $67.00, indicating a potential upside of 162.75%. Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 305.41%. Given Pasithea Therapeutics’ higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Forte Biosciences.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Forte Biosciences | N/A | -75.64% | -65.94% |
| Pasithea Therapeutics | N/A | -97.88% | -87.96% |
Risk & Volatility
Forte Biosciences has a beta of 3.23, suggesting that its stock price is 223% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.
Earnings & Valuation
This table compares Forte Biosciences and Pasithea Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Forte Biosciences | N/A | N/A | -$35.48 million | ($3.32) | -7.68 |
| Pasithea Therapeutics | N/A | N/A | -$13.90 million | ($5.09) | -0.15 |
Forte Biosciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Forte Biosciences beats Pasithea Therapeutics on 8 of the 11 factors compared between the two stocks.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
